Zovegalisib for PIK3CA-driven vascular and lymphatic malformations: a drug evaluation. (PubMed, Expert Opin Investig Drugs) - Oct 15, 2026 - "PIK3CA-driven overgrowth and vascular malformations are mosaic developmental disorders in which chronic pathway inhibition may be required from childhood into adulthood. Activity after prior sirolimus and/or alpelisib and encouraging short-term tolerability support further development. Mutant selectivity could be especially valuable in chronic nonmalignant disease, but superiority over alpelisib is unproven."
Journal • Review • CNS Disorders • Dental Disorders • Developmental Disorders • Diabetes • Psychiatry • Stomatitis • PIK3CA
|
|
An Van Damme; Emmanuel Seront; Julien Coulie; Laurence M Boon; Miikka Vikkula
|